Abstract Background: Group I metabotropic glutamate receptor (mGluR1 and mGluR5) allosteric modulators are currently being investigated as novel therapeutics for the treatment of neurodevelopmental disorders such as schizophrenia, autism, depression (Cleva and Olive, 2011). Recent evidence suggests that allosteric
modulators have adverse pharmacological effects when bound to the monomeric, compared to the dimeric form of these receptors (El Moustaine et al., 2012) . Investigating the neurodevelopmental expression of dimeric and monomeric mGluR1 and mGluR5 may highlight possible implications for novel therapeutics at critical neurodevelopmental periods. Methods: Pregnant Sprague-Dawley rats were obtained at gestational day 14. Offspring were euthanised on postnatal day (PN) 12, 35 and 96 (n=6/group) coinciding with juvenile, adolescent and adult time points. Immunoblots were performed on prefrontal cortex (PFC) and hippocampal tissue under non-reducing conditions to measure dimeric and monomeric mGluR1 and mGluR5 proteins. Results: Dimeric mGluR1and mGluR5 was expressed in higher abundance than their monomeric forms. mGluR1 dimeric expression was lowest at PN12 in both the PFC and hippocampus; where it displayed an increase with age. Whilst monomeric mGluR1 expression was considerably lower, it showed a similar trend in the PFC, however, its expression remained constant in the hippocampus. In contrast, dimeric mGluR5 protein expression in the PFC peaked at PN12 and decreased throughout the neurodevelopmental time-points, however its expression in the hippocampus remained constant throughout. Interestingly, in both regions mGluR5 monomer was highly expressed at PN12, almost equal to dimeric expression and then declined to the lowest limits of detection at later time-points.
Conclusion:
The monomeric form of mGluR5 is relatively abundant during early post-natal development. Considering positive allosteric modulators exert an unregulated agonist effect when bound to the monomeric form of mGluRs, administration of these compounds during such a critical neurodevelopmental period, may cause seizures and neurotoxic effects, posing possible consequences for novel mGluR5 therapeutics. Abstract To obtain insight into abnormalities in neurodevelopmental trajectories of schizophrenia, analyses of patient-derived human induced pluripotent stem cells (hiPSCs) should be informative. Given the extreme complexity and heterogeneity of genomic architecture underlying 'general schizophrenia', analyses of schizophrenia patients with the 22q11.2 deletion could be beneficial because the deletion is one of the highest risk factors. We established hiPSCs from two schizophrenia patients with the 22q11.2 deletion and three controls. Neurosphere size, neural differentiation efficiency, neurite outgrowth and neurogenicto-gliogenic competence ratio were significantly reduced in the patient-derived cells. As an underlying mechanism, we focused on the role of DGCR8, a key gene for microRNA (miRNA) processing and mapped in the deleted region. In mice, Dgcr8 hetero-knockout is known to show a similar phenotype of reduced neurosphere size. miRNA profiling detected reduced expression levels of miRNAs belonging to miR-17/92 cluster and miR-106a/b in the patient-derived neurospheres. Those miRNAs are reported to target p38α, and conformingly the levels of p38α were upregulated in the patient-derived cells. p38α is known to drive gliogenic differentiation. Inhibition of p38 activity by SB203580 in patient-derived neurospheres partially restored neurogenic competence. Furthermore, we confirmed an elevated expression of GFAP, a gliogenic (astrocyte) marker, in postmortem brains from schizophrenia patients. These results suggest that a dysregulated balance of neurogenic and gliogenic competences may underlie 'general' schizophrenia.
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Interactions of tardive dyskinesia with cognitive function in patients with schizophrenia: worsening of working memory with clozapine treatment ) was reported to improve less than SCZ without TD (SCZ-TD¯) on some cognitive tests during treatment with antipsychotic drugs (APDs) other than clozapine (Caroff et al., J Clin Psychiatry, 2011) . Clozapine improves some cognitive functions, especially, verbal fluency (VF). It improves working memory (WM) in the subset of patients who have higher N-desmethylclozapine (NDMC)/clozapine plasma ratio (Meltzer, Am J Psychiatry, 2015) . However, overall, it worsens WM (Hagger et al., Biol Psychiatry, 1993) . We have, now, examined the impact of TD on cognition after 6 wks of clozapine treatment, with special attention to WM and VF, along with assessments of the impact of clozapine and NDMC levels, and their ratio on cognition in a subsample. Methods: One hundred seventeen patients (24 SCZ-TD + ) were administrated a comprehensive cognitive, as well as psychopathology, assessments, at baseline and after 6 wks of clozapine treatment. Drug concentrations were measured in a subsample at 6 wk. Results: At baseline, SCZ-TD + showed significantly lower scores on the Controlled Word Association Test (CWAT), a phonemic VF test, compared to SCZ-TD¯ (p=0.003). No other cognitive test differed significantly between groups. At 6 wk, clozapine significantly improved CWAT (p<0.02) and worsened Consonant Trigram Test (CTT) (p<0.03), a verbal WM test, in both groups. In addition, their changes at 6 wk were negatively correlated (p<0.03). TD + was associated with significantly greater worsening of performance on the CTT (p=0.05). Plasma drug levels and their ratio were not different between groups, and was not associated with CTT or CWAT at 6 wk. TD status did not affect psychopathology at baseline or at 6 wk. Conclusions: These data provide new evidence that dorsal striatal deficits, which underlie TD, may be related to cognitive impairment mediated via frontostriatal network in SCZ-TD + . They reinforce the need for less use of typical APDs, which has an increased risk for TD, and the need to take TD status into account in assessing cognition in SCZ and related disorders. (Ikemoto et al. 1997 (Ikemoto et al. , 2016 ), and to show D-neuron decrease in the nucleus accumbens (Acc) (D16, subgroup of D-neurons) of postmortem brains with schizophrenia (Ikemoto et al. 2003) . The human D-neuron system is found to be far developed in the forebrain in comparison with that of other species, including non-human primates (Kitahama et al.2009 ). TA decrease caused by D-neuron reduction, and consequent TAAR1 stimulation decrease on terminals of midbrain VTA DA neurons leads to mesolimbic DA hyperactivity. Neural stem cell (NSC) dysfunction in the subventricular zone of lateral ventricle, which overlaps with the Acc, is supposed to be the cause of D-neuron reduction of schizophrenia. The rational is that the "D-cell hypothesis (TA hypothesis)" (Ikemoto 2012) is essential hypothesis to link DA hypothesis (Hokfelt et al, 1974) with NSC dysfunction hypothesis (Reif et al. 2006) . From a therapeutic direction, (1) TAAR1 agonists or TAAR1 partial agonists (Revel et al. 2013) , (2) DA D2 antagonists, and (3) neurotropic substances (e.g., brainderived neurotrophic factor (BDNF), lithium, anticonvulsants, and antidepressants) have potential to normalize mesolimbic DA hyperactivity. Intranasal administration of these neuroactive substances and/or their precursors to reach the neuroleptic acting site, such as the subventricular-accumbal region, by using nanotechnology, is a possible prospective therapeutic strategy, which is devoid of gastrointestinal side effects.
